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Effect of FGF21 on metabolic syndrome patients is not exactly clear. In the 
present study, we assessed serum level of fibroblast growth factor 21 in type 2 
diabetic patients with and without metabolic syndrome in Gorgan. The study 
groups consisted of 120 patients with type 2 diabetes and 60 healthy subjects. 
Diabetic patients divided into two groups. All subjects were matched according 
to age and sex. The mean waist circumference, systolic and diastolic blood 
pressure, triglyceride and fasting blood glucose levels and body mass index were 
significantly higher in the subjects with metabolic syndrome than control group, 
but the mean HDL-cholesterol was significantly lower (p = 0.0001). Mean serum 
level of FGF21 was higher in type 2 diabetic subjects with and without metabolic 
syndrome than that of control subject (p = 0.0001). There were significant 
negative correlation between FGF21 and BMI, diastolic blood pressure  and 
HDL-cholesterol in subjects with metabolic  syndrome  (p<0.05). There were 
also significant negative correlation between  FGF21  and cholesterol and 
HDL-cholesterol in control group (p<0.05). The findings of this study suggest that 
serum FGF21 are higher in patients with type 2 diabetes with and without 
metabolic syndrome than in age and sex matched control group. Our study shows 
that some of metabolic syndrome components (especially HDL-cholesterol) are 
associated with high serum FGF21 levels. Because of different effects of FGF21 
in rodents, primates and in humans, it may require more investigating on 
metabolic effects of FGF21 in human's samples. 
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INTRODUCTION 
The metabolic syndrome consisted of some metabolic 
abnormalities such as hypertension, dyslipidaemia, 
obesity, insulin resistance and high fasting plasma glucose 
(Miranda et al., 2005). It has been reported that genetic 
differences, diet, physical activity, age and sex affect the 
prevalence of metabolic syndrome and its components 
(Cameron et al., 2004). Many studies showed that 
metabolic syndrome changes in different ethnic and age 
groups and postmenopausal women (Marjani, 2005a, b, 
2006a, b; Marjani et al., 2007a, b, c, 2008, 2010). The 
role of Fibroblast Growth Factor 21 (FGF21) was first 
reported in 2005. Glucose uptake was stimulated by FGF 
21 in human and mouse adipocytes (Chen et al., 2011). 
The FGF 21 is encoded by chromosome 19. Production of 
this factor takes place in the liver, white adipose tissue, 
skeletal muscle and pancreas. Glucose and lipid 
metabolism regulation  may  depend on FGF21 
(Iglesias et al., 2012). Some studies have shown that 
fasting and feeding may regulate FGF21 expression 
(Uebanso et al., 2011). This factor may be a risk factor for 
some diseases like insulin resistance, type 2 diabetes 
mellitus and metabolic syndrome (Mraz et al., 2009; 
Bobbert et al., 2013). Some studies have revealed that 
serum FGF21 influenced by high blood glucose, increased 
body mass index, uric acid level and low physical activity 
(Cuevas-Ramos et al., 2010). It has shown that FGF21 
may effects endocrine pancreas function. Short-term 
treatment with FGF21 can reduce plasma insulin levels 
(Kharitonenkov et al., 2008). Some studies on rodents and 
primates have shown that FGF21 could have effect on 
carbohydrate and lipid metabolism (Badman et al., 2007; 
Inagaki et al., 2007; Lundasen et al., 2007). Studies on 
mice were indicated that FGF21 prevents hepatic glucose 
production, liver glycogen reduction and decrease 
glucagon level (Berglund et al., 2009). Several 
investigations on diabetic and obese rodents revealed that 
FGF21 reduces plasma triglyceride, free fatty acids and 
cholesterol levels (Kharitonenkov et al., 2005; Xu et al., 
2009). Chronic therapy with FGF21 on diabetic rhesus 
monkeys showed that this factor causes a decrease in 
triglyceride and LDL-cholesterol levels and an increase in 
HDL-cholesterol level (Kharitonenkov et al., 2007). In 
studies on human have shown that lipolysis inhibition in 
adipocytes takes place by FGF21 (Arner et al., 2008), 
while other findings have indicated that high level of 
serum FGF21 associated with abdominal adiposity, 
insulin resistance, high level  of triglyceride and 
type 2 diabetes (Jian et al., 2012; Chavez et al., 2009; 
Dushay et al., 2010; Galman et al., 2008; Li et al., 2012; 
Zhang et al., 2008). It is reported that FGF21 are 
associated with metabolic syndrome patients (Chen et al., 
2008), type 2 diabetes (Li et al., 2010), impaired glucose 
tolerance (Chavez et al., 2009), nonalcoholic fatty 
liver disease (Dushay et al., 2010; Li et al., 2011; 
Yilmaz et al., 2010; An et al., 2012) and carotid artery 
disease (Yang et al., 2011; Expert Panel on Detection, 
Evaluation and Treatment of High Blood Cholesterol in 
Adults, 2001). Effect of FGF21 in human on metabolic 
syndrome patients is not exactly clear. In the present 
study, we assessed serum level of fibroblast growth factor 
21 in type 2 diabetic patients with and without metabolic 
syndrome in Gorgan. 
MATERIALS AND METHODS 
The study groups consisted of 120 patients with type 
2 diabetes and 60 healthy subjects. Diabetic patients 
divided into two groups. The control group had no 
hepatic, renal or any other diseases. All subjects were 
matched according to age and sex. All subjects gave 
informed consent to take part in the study. Blood samples 
were provided from all subjects after a 12 h fasting. 
Serum glucose, Total Cholesterol (TC) and High Density 
Lipoprotein Cholesterol (HDL-C), Low Density 
Lipoprotein Cholesterol (LDL-C), triglycerides (TG), 
were determined using commercial kits and 
spectrophotometer technique in the Metabolic Disorders 
Research Center, Gorgan Faculty of Medicine. Serum 
FGF21 was determined by ELISA kit. It provided from 
Bioassay Technology Laboratory (Shanghai Crystal Day 
Biotech Co., LTD, China). The metabolic syndrome 
diagnostic criteria were used as suggested by ATP III 
(Adult Treatment Panel III) (Altekin et al., 2005), 
including:  (1) Waist  circumference  >102 cm in men 
and >88 cm in women, (2) Serum triglycerides level 
$150 mg dLG1, (3) Low HDL-cholesterol: < 40 mg dLG1 
in men and <50 mg dLG1 in women, (4) Systolic Blood 
Pressure (SBP) $130 mmHg and/or Diastolic Blood 
Pressure (DBP) $85 mmHg or on treatment for 
hypertension and (5) Serum glucose level $110 mg dLG1 
or on treatment for diabetes. Subjects with any 3 or more 
of the above mentioned criteria specified as a metabolic 
syndrome subject. A digital scale was used to determine 
weight in all subjects, while they were minimally clothed 
without shoes. Height was measured in standing position 
using tape meter while the shoulder was in a normal 
position. Body Mass Index (BMI) was determined as 
weight in kilograms divided by  height  in meters 
squared.  Overweight and obese were specified as 
BMI = 25.0-29.9 and $30 kg mG2, respectively 
(WHO., 1998).  Waist  circumferences  were  measured 
at the point halfway between the lower border of 
ribs and the iliac crest in a horizontal plane 
(Ryden, 2009). Systolic and diastolic blood pressure was 
measured by using a standard mercury manometer with 
study groups in sitting  position, from  their right hands. 
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SPSS- 18 version software was used to calculate statistical blood glucose levels and BMI were significantly higher in 
analysis (as means and standard deviations). The the subjects with metabolic syndrome than control group, 
association of serum FGF21 level and components of but the  mean  HDL-cholesterol was significantly lower 
metabolic syndrome and other parameters was done by (p = 0.0001). Mean serum level of FGF21 were higher in 
using Pearson’s correlation test. One way analysis of type 2 diabetic subjects with and without metabolic 
variance (ANOVA) followed by Post Hoc Tukey’s test syndrome than that of control subject (p = 0.0001). 
was used to test the differences between groups. p-value Correlation between metabolic syndrome components and 
lower than 0.05 was considered statistically significant. serum FGF21 in control group and subjects with and 
without metabolic syndrome are summarized in Table 2. 
RESULTS There were significant negative correlation between 
FGF21 and BMI, diastolic blood pressure and 
Table 1 shows the clinical and biochemical data of HDL-cholesterol in subjects with metabolic syndrome 
type 2 diabetic subjects with metabolic syndrome and (p<0.05). There were also significant negative correlation 
control group. The mean waist circumference, systolic between FGF21 and cholesterol and HDL-cholesterol in 
and diastolic blood pressure,  triglyceride and fasting control group (p<0.05). 
Table 1: Clinical and biochemical data of type 2 diabetic subjects with and without metabolic syndrome and control group 
Diabetic subjects with Diabetic subjects without p-value between p-value between 2 
Parameters Control groups metabolic syndrome metabolic syndrome all groups groups 
Age (years) 48.51±6.78 52.18±9.80 49.91±10.19 0.085 P1:0.071 
P2:0.675 
P3:0.358 
Waist circumference (cm) 84.85±8.07 103.12±13.78 92.70±8.70 0.0001 P1:0.0001 
P2:0.0001 
P3:0.0001 
BMI (kg mG2) 26.19±3.40 30.60±3.89 28.19±3.98 0.0001 P1:0.0001 
P2:0.011 
P3:0.002 
Systolic blood pressure (mm Hg) 116.40±10.34 125.50±23.79 116.80±11.45 0.003 P1:0.008 
P2:0.992 
P3:0.011 
Diastolic blood pressure (mm Hg) 76.76±7.08 80.63±11.14 74.80±8.55 0.002 P1:0.054 
P2:0.463 
P3:0.002 
Fasting blood glucose (mg dLG1) 87.65±9.59 131.46±54.78 159.38±57.81 0.0001 P1:0.0001 
P2:0.0001 
P3:0.003 
Triglyceride (mg dLG1) 99.61±33.41 200.43±84.49 143.68±61.06 0.0001 P1:0.0001 
P2:0.001 
P3:0.0001 
Cholesterol (mg dLG1) 170.45±37.05 179.80±38.88 175.75±42.57 0.432 P1:0.400 
P2:0.744 
P3:0.841 
HDL-Cholesterol (mg dLG1) 54.06±10.08 44.22±11.10 53.21±13.04 0.0001 P1:0.0001 
P2:0.914 
P3:0.0001 
LDL-Cholesterol (mg dLG1) 101.17±48.15 99.28±47.14 95.52±38.85 0.784 P1:0.972 
P2:0.772 
P3:0.892 
FGF21 533.90±55.39 772.96±62.85 622.00±61.34 0.0001 --­
P1: Comparison between control group and diabetic subjects with metabolic syndrome, P2: Comparison control group and diabetic subjects, without 
metabolic syndrome and P3: Comparison of diabetic subjects with and without metabolic syndrome, BMI: Body mass index 
Table 2: Fibroblast growth factor 21 correlated with metabolic syndrome components of control group, type 2 diabetic subjects with and without metabolic syndrome 
Waist BMI Systolic Diastolic blood Triglyceride Cholesterol HDL-C LDL-C Glucose 
Groups Age (years) circumference (cm) (kg mG2) blood pressure pressure ---------------------------------(mg dLG1)------------------------------­
Control group p = 0.840 p = 0.701 p = 0.317 p = 0.701 p = 0.128 p = 0.836 p = 0.036 p= 0.033 p = 0.052 p = 0.396 
r = 0.026 r = -0.051 r = -0.131 r = 0.051 r = 0.198 r = 0.027 r = -0.271 r= -0.275 r = 0.252 r = 0.111 
Diabetic subjects p = 0.221 p = 0.875 p = 0.040 p = 0.308 p = 0.028 p = 0.814 p = 0.704 P=0.046 p =0.283 p = 0.241 
with metabolic r = 0.160 r = 0.021 r = -0.266 r = -0.134 r = -0.284 r = -0.031 r = 0.050 r= -0.259 r = 0.142 r = -0.154 
syndrome 
Diabetic subjects p = 0.858 p = 0.467 p = 0.797 p = 0.312 p = 0.412 p = 0.547 p = 0.424 p=0.645 p = 0.484 p = 0.288 
without metabolic r = 0.024 r = -0.096 r = 0.034 r = 0.133 r = 0.108 r = 0.079 r = -0.105 r= 0.061 r = -0.093 r = 0.140 
syndrome 
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DISCUSSION 
Fibroblast Growth Factors (FGFs), as new proteins, 
include FGF19, FGF21 and FGF23. Endocrine FGFs can 
bind weakly to heparin/heparin sulfate, which allows 
them to function as endocrine factors (Coskun et al., 
2008). It is not clear that the elevations of FGF21 levels 
are related to FGF21 resistance or to the metabolic 
disorders. Many studies reported that FGF21 shows 
functions such as metabolic regulator or as a biomarker of 
metabolic diseases. The metabolic effects of FGF21 were 
first recognized in murine studies (Li et al., 2008). The 
FGF21 causes stimulation of insulin-independent glucose 
uptake by increasing GLUT-1 expression, reduce blood 
glucose and triglyceride levels in obese mice and reduce 
body weight (Kharitonenkov et al., 2005). Serum FGF21 
shows metabolic effects in different animal models of 
obesity and diabetes mellitus. It has reported that 
expression and regulation of FGF21 in human seems to be 
different when compare to animal models. This may open 
an idea for discussions about the possible clinical roles of 
FGF21. In our study, no significant differences in age, 
BMI and systolic and diastolic blood pressures, 
cholesterol and HDL-cholesterol were seen between the 
patients without metabolic syndrome and control group. 
The mean Body Mass Index (BMI) was lower in the 
control group than the patient groups. The FGF21levels of 
the patients were significantly  higher than those of the 
control group (p = 0.0001 for all). There was a 
significant negative correlation between serum FGF21 
and BMI, diastolic blood  pressure and HDL-cholesterol 
in the group of patients with metabolic  syndrome 
(r = 0.266 p = 0.040,  r  =  0.284 p = 0.028 and r = 0.259 
p = 0.046 r = 0.498, resp). 
In the present  study, we showed that serum 
FGF-21 levels in humans are increased in diabetic 
subjects and are negatively correlated with some 
components of metabolic syndrome. This is in agreement 
with the results of other findings (Chen et al., 2011; 
Zhang et al., 2008) that indicated increased plasma 
FGF-21 level in obesity and type 2 diabetes mellitus. Our 
study is also in agreement with previous findings in Asian 
populations, in which elevated plasma FGF-21 levels 
were observed in treated type 2 diabetic subjects (Li et al., 
2008, 2009; Zhang et al., 2008; Chavez et al., 2009). 
Study of FGF-21 level in rodent models showed that 
FGF-21 increases GLUT4 expression in adipocytes. 
Findings of Arner et al. (2008) indicated that FGF-21 
inhibits lipolysis in human adipocytes. They mentioned 
that this may help to cause the protein’s insulin-
sensitizing effect in humans. Study in animal models of 
FGF-21 has been indicated that FGF-21 has glucose-
lowering effects which are mediated by its actions on liver 
(Eto et al., 2010; Kharitonenkov et al., 2005). The 
different findings of many studies in humans and in 
animal models may express difference in the metabolic 
influences of FGF-21 in humans  and animals  studies. 
No significant correlation was found between serum 
FGF-21 levels and age, waist circumference, fasting 
glucose, triglyceride, cholesterol, LDL-cholesterol levels 
in subjects with metabolic syndrome. In our study, we did 
not also find any correlation between serum FGF-21 and 
serum fasting glucose levels in all groups, which is in 
accordance with the results of the Galman et al. (2008). 
This means that FGF21 may has no effect on glucose 
metabolism which is especially important in type 2 
diabetic subjects. The serum FGF21 levels were 
significantly higher in diabetic subjects with metabolic 
syndrome and correlated negatively with HDL cholesterol 
(Zhang et al., 2008; Li et al., 2009), while some other 
studies showed that serum FGF21 level was associated 
with triglycerides (Eto et al., 2010; Stein et al., 2010). 
Study of Chen et al. (2008) showed a negative correlation 
between serum FGF21 levels and fasting plasma glucose 
levels. Our results are not in agreement with the findings 
of other studies (Eto et al., 2010; Stein  et  al., 2010; 
Chen  et  al., 2008). The elevation of FGF21 levels in 
type 2 diabetic patients may be associated with a 
compensatory response, FGF21 resistance (Chavez et al., 
2009; Chen et al., 2011).Studies on animal models have 
indicated that FGF21 is expressed in the pancreas 
(Tacer et al., 2010) to protect the mass and function of 
pancreatic beta-cells (Wente et al., 2006). The increased 
serum FGF-21 level in diabetic patients may prevent the 
abnormal metabolic process by causing to improve lipid 
profile. (Titan et al., 2011). Studies in human subjects 
suggested that FGF-21 may be a metabolic regulator that 
plays an important role in metabolic process such as lipid 
and energy metabolism. Some studies showed increased 
FGF-21 levels in patients with obesity and T2DM 
(Zhang et al., 2008; Chen et al., 2008). The FGF-21 level 
was indicated to be associated with several symptoms of 
metabolic syndrome (Zhang et al., 2008). However, other 
studies revealed that FGF-21 was positively associated 
with metabolic disorders, including dyslipidemia, obesity, 
high plasma glucose level and insulin resistance 
(Dostalova et al., 2008; Mai et al., 2011; Chavez et al., 
2009). The cause of these discrepancies is still unclear. 
There are different findings about FGF-21 in human and 
other mammals. The results of our study differed 
considerably from those obtained in mice, suggesting that 
the physiologic role of FGF-21 in humans may differ 
from that in animals. In this study, we found that FGF-21 
level negatively correlated with HDL-C level, which was 
inconsistent with the beneficial metabolic function of 
FGF-21 in rodents (Coskun et al., 2008). 
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CONCLUSION 
The findings of this study suggest that serum FGF21 
are higher in patients with type 2 diabetes with and 
without metabolic syndrome than in age and sex matched 
control group. Our study shows that some of metabolic 
syndrome components (especially HDL-cholesterol) are 
associated with high serum FGF21 levels. Because of 
different effects of FGF21 in rodents, primates and in 
humans, it may require more investigating on metabolic 
effects of FGF21 in human's samples. 
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